Digitalis glycosides have been used for more than 200 years to treat chronic congestive heart failure although they often fail to provide adequate support in a patient with a severely depressed heart at the dose that does not cause toxicity. Improvement of this class of drugs is not feasible because both the therapeutic and toxic actions are caused by the same mechanism, i.e., inhibition of the sarcolemmal sodium pump. Despite the initial optimism with "newer" positive inotropic drugs, they are not free from toxicity which is caused by Ca2+ overload or from their tendency to inhibit relaxation. Moreover, these drugs fail to reduce risk factors in patients with advanced heart failure. Mortality of these patients is reduced by vasodilator therapy combined with digitalis and a diuretic. This therapy reduces preload and afterload, and hence workload, in addition to increasing the force of myocardial contraction, and minimizes deficiencies of failing heart. In this regard, importance of nonpharmacologic therapies for re duction of cardiac workload should also be emphasized. All these treatments, however, are palliative. We know very little about the basic changes that lead to heart failure, and treatments to prevent those changes are presently un available.
Introduction

Congestive
heart failure, or chronic circulatory insufficiency, occurs when the heart muscle cannot develop sufficient pumping force to deliver an adequate blood supply to various organs. Because the underlying deficiency is a reduction in myocardial con tractility, it would appear logical to treat the condition with cardiac positive inotropic agents. Underlying pathological conditions may vary, but clinical symptoms are similar.
These include fatigue, reduced exercise tolerance, shortness of breath, edema of lower extremities and finally pulmonary edema. It was these types of edema, William
Withering1 found some 200 years ago, that could be successfully remedied by the leaves of foxglove (digitalis). He also noted that the drug retards the pulse "to an alarming degree without any preceding effect." Effects of digitalis on the heart muscle had been suggested by many: in 1938 Cattell and Gold2 unequivocally demonstrated that the primary site of the beneficial action of digitalis was the cardiac muscle. Following the purification of the digitalis glycosides, digoxin and digitoxin became the mainstay of therapy for congestive heart failure.3
During congestive heart failure, several mechanisms are triggered in an attempt to compensate for the inability of the heart to pump adequate amounts of blood. First, end-diastolic volume increases. This increase in "preload" causes the heart muscle to contract with a greater force, as indicated by the Frank-Starling's law, at the expense of a decreased energetic efficiency. In addition, the intravascular blood volume, and therefore preload, may also be increased by activation of the renin-angiotensin-aldo sterone axis. Sympathetic tone also increases, forcing the heart to work harder to eject enough blood, again at the expense of decreased energetic efficiency. The cardiac glycoside restores myocardial contractility and reverses all these symptoms if the under lying pathological changes are not too extensive.
The glycosides, however, are by no means "ideal" drugs. They have inherent and notorious tendency to produce toxicity. When a patient is given about 70 percent above the "optimal" dose of digitalis, severe toxicity may result. Thus, the glycoside, with a calculated therapeutic index (the ratio between toxic and therapeutic doses) of ap proximately 1.7, is among the most toxic drugs in current use. Intoxication due to overdose of digitalis is a frequent, serious and potentially fatal complication of its thera peutic use.
Attempts to improve digitalis glycosides
The adverse reaction to the digitalis glycoside includes symptoms of central origin such as anorexia, nausea, vomiting, weakness and yellow vision. The major toxicity of digitalis, however, is characterized by various types of cardiac arrhythmias. The treat ment of congestive heart failure is frequently initiated by the concurrent use of digitalis and diuretics. Such combined therapy is dramatically effective. Edema, typical of con gestive heart failure, normally disappears within a week, and the general condition of the patient improves. At this time, however, the plasma potassium concentration is lowered because of the combined action of digitalis and diuretics. The primary mechanism responsible for the positive inotropic action of the cardiac glycosides is the inhibition of the cardiac sarcolemmal sodium pump.7 A 20 to 40% inhibition of the pump causes a 10 to 20% increase in the intracellular Na+ concentra tion observed during the diastolic phase.8 During this phase, the Na+/Ca2+ exchange mechanism in the sarcolemma normally mediates Na+ influx coupled with Ca2+ efffux.9
Therefore, an elevation of the intracellular Na+ is likely to reduce the amount of Ca2+ to be extruded by the exchange mechanism. This may cause an extra amount of Ca2+ to be taken up by the sarcoplasmic reticulum. If this sequence of events occur, it will increase the amount of Ca2+ to be released from the sarcoplasmic reticulum triggered by membrane excitation, and thereby increases the force of myocardial contraction.
The above hypothesis is supported by findings (1) that digitalis preferentially in creases developed tension that is dependent on Ca2+ released from the sarcoplasmic reticulum over that which is dependent on transmembrane Ca2+ influx10 and (2) that digitalis increases cellular Ca2+ during the diastolic phase instead of increasing Ca2+ influx during membrane excitation.11,12 Digitalis does increase intracellular Ca2+ tran sients; however, this is the result of the increased Ca2+ loading of, and Ca2+ release from, the sarcoplasmic reticulum.
The mechanisms for the toxic actions of the cardiac glycosides are more complex involving both direct actions on the heart muscle and indirect actions on the autonomic system. Ventricular tachyarrhythmias are the most prominent toxic effect of the cardiac glycoside resulting from its direct action. A popular hypothesis is that a toxic con centration of the cardiac glycoside causes a 60-80% inhibition of the sodium pump, modifies Na+/Ca2+ exchange, increases the diastolic Ca2+ concentration in the cytoplasm, When failing heart muscle cannot develop a force sufficient to meet demand, posi tive inotropic drugs may be used to increase myocardial contractility. Alternatively, the demand, or the afterload and perhaps preload, may be reduced such that the force of failing heart becomes sufficient to provide the necessary cardiac output. Therefore, nonpharmacologic therapies such as reducing physical activity, instituting emotional rest and restricting salt and water intake are important. Pharmacological reduction of cardiac workload can be achieved by lowering the blood pressure, dilating blood vessels and reducing circulating blood volume. A combination of various antihypertensive drugs and diuretics may be used for this purpose. The therapy is apparently successful.
Moreover, vasodilator therapy with a combination of hydralazine (300mg per day) and isosorbide dinitrate (160mg per day) has been shown to reduce mortality of pa tients with chronic congestive heart failure receiving digoxin and a diuretic.26 One problem with the inotropic drugs is that they represent palliative forms of therapy.
The inotropic drugs force the failing heart to work harder without correcting the under lying pathophysiological changes that are responsible for the failure of the myocardium.
In this regard, vasodilator therapy, although also a symptomatic treatment, offers the advantage of reducing the work load of the failing heart, and this appears to contribute to the risk reduction.
Apparently, the best therapeutic regimen available today is vasodilator therapy combined with the cardiac glycoside and a diuretic. Therefore, it is necessary to under stand the basis for rational therapy with the cardiac glycosides in order to take full advantage of the combination therapy.
Rational use of digitalis glycosides
The Na+,K+-ATPase inhibition by the cardiac glycoside undoubtedly increases myocardial contractility; however, the role of digitalis therapy in the management of patients with heart failure who remain in sinus rhythm has been controversial. This is because full inotropic effects to support moderately or severely depressed heart may not be obtained in patients owing to the low therapeutic indices of the cardiac glycosides.
Serum concentrations of digoxin and digitoxin associated with the appearance of serious toxicity are 2ng/ml and 20ng/ml, respectively. With a calculated therapeutic index of approximately 1.7, at least 50% of the above concentration is required to obtain the positive inotropic effect. Therefore, it is necessary to maintain the serum glycoside concentration within a narrow range during chronic treatment. This task is complicated by variations in the pharmacokinetics of the cardiac glycosides.
The absorption of digoxin following oral administration varies from 45 to 85% depending upon the individual and the type of preparation used. Differences in bio availability of digoxin tablets has been a problem, but is anticipated to be reduced in the future. Absorption is nearly complete with digitoxin, which has a higher lipid solubility compared to digoxin. Differences in the rate and extent of absorption, and also differences in renal clearance should be considered when digoxin is used, and differences in hepatic function, and ensuing variations in the rate of metabolism should be considered for digitoxin.
Development of radioimmunoassay methods for digoxin and digitoxin now provide a means for circumventing pharmacokinetic problems. By re-adjusting the dosage schedule using the feedback from plasma glycoside concentrations, it is possible to achieve a predetermined concentration (target concentration strategy). This approach, however, does not solve the problem that a given serum concentration of the glycoside may cause either a therapeutic or toxic effect. Therefore, it is important to know the nature and extent of changes in digitalis sensitivity of the myocardium under various to identify those changes that are desirable and those which contribute to the process that causes the heart to fail, and to find a means of modifying the latter process.
